{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:20:30Z","timestamp":1790022030268,"version":"4.0.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-024-00811-0","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T12:10:11Z","timestamp":1731586211000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Cinnamaldehyde ameliorates diabetes-induced biochemical impairments and AGEs macromolecules in a pre-clinical model of diabetic nephropathy"],"prefix":"10.1186","volume":"25","author":[{"given":"Noor","family":"Fatima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Israr","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hira","family":"Jawed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urooj","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaheer","family":"Ul-Haq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahman M.","family":"Hafizur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tawaf Ali","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Musaab","family":"Dauelbait","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousef A.","family":"Bin Jardan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gamal A.","family":"Shazly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,14]]},"reference":[{"issue":"1","key":"811_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13036-022-00299-4","volume":"16","author":"HY Thomas","year":"2022","unstructured":"Thomas HY, Ford Versypt AN. Pathophysiology of mesangial expansion in diabetic nephropathy: mesangial structure, glomerular biomechanics, and biochemical signaling and regulation. J Biol Eng. 2022;16(1):19. https:\/\/doi.org\/10.1186\/s13036-022-00299-4.","journal-title":"J Biol Eng"},{"issue":"5","key":"811_CR2","doi-asserted-by":"publisher","first-page":"F831","DOI":"10.1152\/ajprenal.00313.2016","volume":"311","author":"CB Marshall","year":"2016","unstructured":"Marshall CB. Rethinking glomerular basement membrane thickening in diabetic nephropathy: adaptive or pathogenic? Am J Physiol Renal Physiol. 2016;311(5):F831\u2013F843. https:\/\/doi.org\/10.1152\/ajprenal.00313.2016.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"47","key":"811_CR3","doi-asserted-by":"publisher","first-page":"28228","DOI":"10.1074\/jbc.270.47.28228","volume":"270","author":"HS Yim","year":"1995","unstructured":"Yim HS, Kang SO, Hah YC, Chock PB, Yim MB. Free radicals generated during the glycation reaction of amino acids by methylglyoxal. A model study of protein-cross-linked free radicals. J Biol Chem. 1995;270(47):28228\u201333. https:\/\/doi.org\/10.1074\/jbc.270.47.28228.","journal-title":"J Biol Chem"},{"key":"811_CR4","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.redox.2013.12.016","volume":"2","author":"C Ott","year":"2014","unstructured":"Ott C, Jacobs K, Haucke E, Santos AN, Grune T, Simm A. Role of advanced glycation end products in cellular signaling. Redox Biol. 2014;2:411\u201329.","journal-title":"Redox Biol"},{"issue":"5","key":"811_CR5","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/ncpendmet0786","volume":"4","author":"SF Yan","year":"2008","unstructured":"Yan SF, Ramasamy R, Schmidt AM. Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat Clin Pract Endocrinol Metab. 2008;4(5):285\u201393. https:\/\/doi.org\/10.1038\/ncpendmet0786.","journal-title":"Nat Clin Pract Endocrinol Metab"},{"issue":"6","key":"811_CR6","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/0272-6386(95)90051-9","volume":"26","author":"R Bucala","year":"1995","unstructured":"Bucala R, Vlassara H. Advanced glycosylation end products in diabetic renal and vascular disease. Am J Kidney Dis. 1995;26(6):875\u201388. https:\/\/doi.org\/10.1016\/0272-6386(95)90051-9.","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"811_CR7","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1172\/JCI119853","volume":"100","author":"K Horie","year":"1997","unstructured":"Horie K, Miyata T, Maeda K, Miyata S, Sugiyama S, Sakai H, De Strihou CVY, Monnier VM, Witztum JL, Kurokawa K. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy. J Clin Invest. 1997;100(12):2995\u20133004.","journal-title":"J Clin Invest"},{"key":"811_CR8","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.biopha.2018.07.157","volume":"107","author":"B Giri","year":"2018","unstructured":"Giri B, Dey S, Das T, Sarkar M, Banerjee J, Dash SK. Chronic hyperglycemia mediated physiological alteration and metabolic distortion leads to organ dysfunction, infection, cancer progression and other pathophysiological consequences: an update on glucose toxicity. Biomed Pharmacother. 2018;107:306\u201328. https:\/\/doi.org\/10.1016\/j.biopha.2018.07.157.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"811_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4196\/kjpp.2014.18.1.1","volume":"18","author":"VP Singh","year":"2014","unstructured":"Singh VP, Bali A, Singh N, Jaggi AS. Advanced glycation end products and diabetic complications. Korean J Physiol Pharmacol KJPP. 2014;18(1):1\u201314. https:\/\/doi.org\/10.4196\/kjpp.2014.18.1.1.","journal-title":"Korean J Physiol Pharmacol KJPP"},{"issue":"2","key":"811_CR10","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s12276-021-00561-7","volume":"53","author":"W Rungratanawanich","year":"2021","unstructured":"Rungratanawanich W, Qu Y, Wang X, Essa MM, Song BJ. Advanced glycation end products (AGEs) and other adducts in aging-related diseases and alcohol-mediated tissue injury. Exp Mol Med. 2021;53(2):168\u201388. https:\/\/doi.org\/10.1038\/s12276-021-00561-7.","journal-title":"Exp Mol Med"},{"issue":"8","key":"811_CR11","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.3390\/cells11081312","volume":"11","author":"A Twarda-Clapa","year":"2022","unstructured":"Twarda-Clapa A, Olczak A, Bia\u0142kowska AM, Kozio\u0142kiewicz M. Advanced Glycation End-Products (AGEs): formation, chemistry, classification, receptors, and diseases related to AGEs. Cells. 2022;11(8):1312.","journal-title":"Cells"},{"issue":"3","key":"811_CR12","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.cmet.2018.08.014","volume":"28","author":"J Chaudhuri","year":"2018","unstructured":"Chaudhuri J, Bains Y, Guha S, Kahn A, Hall D, Bose N, Gugliucci A, Kapahi P. The role of advanced glycation end products in aging and metabolic diseases: bridging association and causality. Cell Metab. 2018;28(3):337\u201352. https:\/\/doi.org\/10.1016\/j.cmet.2018.08.014.","journal-title":"Cell Metab"},{"issue":"4","key":"811_CR13","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1210\/jc.2007-1817","volume":"93","author":"S-Y Goh","year":"2008","unstructured":"Goh S-Y, Cooper ME. The role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab. 2008;93(4):1143\u201352.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"811_CR14","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S0002-9440(10)65659-3","volume":"153","author":"N Sasaki","year":"1998","unstructured":"Sasaki N, Fukatsu R, Tsuzuki K, Hayashi Y, Yoshida T, Fujii N, Koike T, Wakayama I, Yanagihara R, Garruto R. Advanced glycation end products in Alzheimer\u2019s disease and other neurodegenerative diseases. Am J Pathol. 1998;153(4):1149\u201355.","journal-title":"Am J Pathol"},{"issue":"1","key":"811_CR15","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3233\/JAD-190639","volume":"72","author":"P-S Chou","year":"2019","unstructured":"Chou P-S, Wu M-N, Yang C-C, Shen C-T, Yang Y-H. Effect of advanced glycation end products on the progression of Alzheimer\u2019s disease. J Alzheimers Dis. 2019;72(1):191\u201397.","journal-title":"J Alzheimers Dis"},{"key":"811_CR16","doi-asserted-by":"publisher","first-page":"938285","DOI":"10.4161\/oxim.3.2.11148","volume":"3","author":"S.-I Yamagishi","year":"2010","unstructured":"Yamagishi S.-I, Matsui T. Advanced glycation end products, oxidative stress and diabetic nephropathy. Oxid Med Cell Longev. 2010;3:938285. https:\/\/doi.org\/10.4161\/oxim.3.2.11148.","journal-title":"Oxid Med Cell Longev"},{"issue":"4","key":"811_CR17","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.cardiores.2004.05.001","volume":"63","author":"G Basta","year":"2004","unstructured":"Basta G, Schmidt AM, De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res. 2004;63(4):582\u201392.","journal-title":"Cardiovasc Res"},{"issue":"7","key":"811_CR18","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.2337\/diabetes.53.7.1813","volume":"53","author":"JM Forbes","year":"2004","unstructured":"Forbes JM, Yee LTL, Thallas V, Lassila M, Candido R, Jandeleit-Dahm KA, Thomas MC, Burns WC, Deemer EK, Thorpe SR. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes. 2004;53(7):1813\u201323.","journal-title":"Diabetes"},{"issue":"24","key":"811_CR19","doi-asserted-by":"publisher","first-page":"6124","DOI":"10.3390\/cancers14246124","volume":"14","author":"Y Peng","year":"2022","unstructured":"Peng Y, Liu F, Qiao Y, Wang P, Du H, Si C, Wang X, Chen K, Song F. Genetically modified circulating levels of advanced glycation end-products and their soluble receptor (AGEs-RAGE Axis) with risk and mortality of breast cancer. Cancers (Basel). 2022;14(24):6124.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"811_CR20","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12872-022-02694-7","volume":"22","author":"LY Li","year":"2022","unstructured":"Li LY, Chen S, Li FF, Wu ZM, Shen Y, Ding FH, Wang XQ, Shen WF, Chen QJ, Dai Y, Lu L. High serum levels of N-epsilon-carboxymethyllysine are associated with poor coronary collateralization in type 2 diabetic patients with chronic total occlusion of coronary artery. BMC Cardiovasc Disord. 2022;22(1):282. https:\/\/doi.org\/10.1186\/s12872-022-02694-7.","journal-title":"BMC Cardiovasc Disord"},{"issue":"4","key":"811_CR21","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1007\/s11606-011-1912-5","volume":"27","author":"EM Abdel-Rahman","year":"2012","unstructured":"Abdel-Rahman EM, Saadulla L, Reeves WB, Awad AS. Therapeutic modalities in diabetic nephropathy: standard and emerging approaches. J Gen Intern Med. 2012;27(4):458\u201368. https:\/\/doi.org\/10.1007\/s11606-011-1912-5.","journal-title":"J Gen Intern Med"},{"key":"811_CR22","doi-asserted-by":"publisher","first-page":"685447","DOI":"10.3389\/fmed.2021.685447","volume":"8","author":"R Nishad","year":"2021","unstructured":"Nishad R, Tahaseen V, Kavvuri R, Motrapu M, Singh AK, Peddi K, Pasupulati AK. Advanced-glycation end-products induce podocyte injury and contribute to proteinuria. Front Med (Lausanne). 2021;8:685447. https:\/\/doi.org\/10.3389\/fmed.2021.685447.","journal-title":"Front Med (Lausanne)"},{"key":"811_CR23","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3389\/fphys.2020.00084","volume":"11","author":"O Foresto-Neto","year":"2020","unstructured":"Foresto-Neto O, Albino AH, Arias SCA, Faustino VD, Zambom FFF, Cenedeze MA, Elias RM, Malheiros D, Camara NOS, Fujihara CK, Zatz R. NF-\u03baB system is chronically activated and promotes glomerular injury in experimental type 1 diabetic kidney disease. Front Physiol. 2020;11:84. https:\/\/doi.org\/10.3389\/fphys.2020.00084.","journal-title":"Front Physiol"},{"issue":"4","key":"811_CR24","doi-asserted-by":"publisher","first-page":"431","DOI":"10.4239\/wjd.v5.i4.431","volume":"5","author":"PM Garc\u00eda-Garc\u00eda","year":"2014","unstructured":"Garc\u00eda-Garc\u00eda PM, Getino-Meli\u00e1n MA, Dom\u00ednguez-Pimentel V, Navarro-Gonz\u00e1lez JF. Inflammation in diabetic kidney disease. World J Diabetes. 2014;5(4):431\u201343. https:\/\/doi.org\/10.4239\/wjd.v5.i4.431.","journal-title":"World J Diabetes"},{"issue":"1","key":"811_CR25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1586\/eem.09.44","volume":"5","author":"S Devaraj","year":"2010","unstructured":"Devaraj S, Dasu MR, Jialal I. Diabetes is a proinflammatory state: a translational perspective. Expert Rev Endocrinol Metab. 2010;5(1):19\u201328. https:\/\/doi.org\/10.1586\/eem.09.44.","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"2","key":"811_CR26","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/sj.eye.6700095","volume":"16","author":"S Doganay","year":"2002","unstructured":"Doganay S, Evereklioglu C, Er H, T\u00fcrk\u00f6z Y, Sevin\u00e7 A, Mehmet N, \u015eavli H. Comparison of serum NO, TNF-\u03b1, IL-1\u03b2, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus. Eye. 2002;16(2):163\u201370. https:\/\/doi.org\/10.1038\/sj.eye.6700095.","journal-title":"Eye"},{"issue":"1","key":"811_CR27","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.cyto.2011.09.029","volume":"57","author":"S Mirza","year":"2012","unstructured":"Mirza S, Hossain M, Mathews C, Martinez P, Pino P, Gay JL, Rentfro A, McCormick JB, Fisher-Hoch SP. Type 2-diabetes is associated with elevated levels of TNF-alpha, IL-6 and adiponectin and low levels of leptin in a population of Mexican Americans: a cross-sectional study. Cytokine. 2012;57(1):136\u201342. https:\/\/doi.org\/10.1016\/j.cyto.2011.09.029.","journal-title":"Cytokine"},{"key":"811_CR28","doi-asserted-by":"publisher","first-page":"609223","DOI":"10.3389\/fphys.2020.609223","volume":"11","author":"RH Aly","year":"2020","unstructured":"Aly RH, Ahmed AE, Hozayen WG, Rabea AM, Ali TM, El Askary A, Ahmed OM. Patterns of toll-like receptor expressions and inflammatory cytokine levels and their implications in the progress of insulin resistance and diabetic nephropathy in type 2 diabetic patients. Front Physiol. 2020;11:609223.","journal-title":"Front Physiol"},{"key":"811_CR29","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.cytogfr.2017.03.003","volume":"37","author":"E Feigerlov\u00e1","year":"2017","unstructured":"Feigerlov\u00e1 E, Battaglia-Hsu S-F. IL-6 signaling in diabetic nephropathy: from pathophysiology to therapeutic perspectives. Cytokine Growth Factor Rev. 2017;37:57\u201365. https:\/\/doi.org\/10.1016\/j.cytogfr.2017.03.003.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"2","key":"811_CR30","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s001250051591","volume":"44","author":"R Singh","year":"2001","unstructured":"Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia. 2001;44(2):129\u201346. https:\/\/doi.org\/10.1007\/s001250051591.","journal-title":"Diabetologia"},{"issue":"1","key":"811_CR31","doi-asserted-by":"publisher","first-page":"26","DOI":"10.2337\/diab.41.1.26","volume":"41","author":"D Edelstein","year":"1992","unstructured":"Edelstein D, Brownlee M. Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine. Diabetes. 1992;41(1):26\u201329. https:\/\/doi.org\/10.2337\/diab.41.1.26.","journal-title":"Diabetes"},{"issue":"5","key":"811_CR32","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/s0197-2456(99)00024-0","volume":"20","author":"BI Freedman","year":"1999","unstructured":"Freedman BI, Wuerth JP, Cartwright K, Bain RP, Dippe S, Hershon K, Mooradian AD, Spinowitz BS. Design and baseline characteristics for the aminoguanidine clinical trial in overt type 2 diabetic nephropathy (ACTION II). Control Clin Trials. 1999;20(5):493\u2013510. https:\/\/doi.org\/10.1016\/s0197-2456(99)00024-0.","journal-title":"Control Clin Trials"},{"issue":"9","key":"811_CR33","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.2337\/diabetes.51.9.2826","volume":"51","author":"A Stitt","year":"2002","unstructured":"Stitt A, Gardiner TA, Alderson NL, Canning P, Frizzell N, Duffy N, Boyle C, Januszewski AS, Chachich M, Baynes JW, Thorpe SR. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes. 2002;51(9):2826\u201332. https:\/\/doi.org\/10.2337\/diabetes.51.9.2826.","journal-title":"Diabetes"},{"issue":"6588","key":"811_CR34","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/382275a0","volume":"382","author":"S Vasan","year":"1996","unstructured":"Vasan S, Zhang X, Zhang X, Kapurniotu A, Bernhagen J, Teichberg S, Basgen J, Wagle D, Shih D, Terlecky I, Bucala R, Cerami A, Egan J, Ulrich P. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature. 1996;382(6588):275\u201378. https:\/\/doi.org\/10.1038\/382275a0.","journal-title":"Nature"},{"issue":"01","key":"811_CR35","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1139\/cjpp-2012-0350","volume":"01","author":"CV Anuradha","year":"2015","unstructured":"Anuradha CV. Phytochemicals targeting genes relevant for type 2 diabetes. Natural Health Product Therapies. 2015;01(01):397\u2013411. https:\/\/doi.org\/10.1139\/cjpp-2012-0350.","journal-title":"Natural Health Product Therapies"},{"issue":"3","key":"811_CR36","doi-asserted-by":"publisher","first-page":"e92358","DOI":"10.1371\/journal.pone.0092358","volume":"9","author":"T Sartorius","year":"2014","unstructured":"Sartorius T, Peter A, Schulz N, Drescher A, Bergheim I, Machann J, Schick F, Siegel-Axel D, Sch\u00fcrmann A, Weigert C, H\u00e4ring HU, Hennige AM. Cinnamon extract improves insulin sensitivity in the brain and lowers liver fat in mouse models of obesity. PLoS One. 2014;9(3):e92358. https:\/\/doi.org\/10.1371\/journal.pone.0092358.","journal-title":"PLoS One"},{"issue":"2","key":"811_CR37","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.phymed.2015.01.003","volume":"22","author":"RM Hafizur","year":"2015","unstructured":"Hafizur RM, Hameed A, Shukrana M, Raza SA, Chishti S, Kabir N, Siddiqui RA. Cinnamic acid exerts anti-diabetic activity by improving glucose tolerance in vivo and by stimulating insulin secretion in vitro. Phytomed. 2015;22(2):297\u2013300. https:\/\/doi.org\/10.1016\/j.phymed.2015.01.003.","journal-title":"Phytomed"},{"issue":"11","key":"811_CR38","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1017\/s0007114508116270","volume":"101","author":"M Saraswat","year":"2009","unstructured":"Saraswat M, Reddy PY, Muthenna P, Reddy GB. Prevention of non-enzymic glycation of proteins by dietary agents: prospects for alleviating diabetic complications. Br J Nutr. 2009;101(11):1714\u201321. https:\/\/doi.org\/10.1017\/s0007114508116270.","journal-title":"Br J Nutr"},{"key":"811_CR39","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3389\/fphar.2018.00008","volume":"9","author":"OL Erukainure","year":"2018","unstructured":"Erukainure OL, Hafizur RM, Kabir N, Choudhary MI, Atolani O, Banerjee P, Preissner R, Chukwuma CI, Muhammad A, Amonsou EO, Islam MS. Suppressive effects of Clerodendrum volubile P Beauv. [Labiatae] methanolic extract and its fractions on type 2 diabetes and its complications. Front Pharmacol. 2018;9:8. https:\/\/doi.org\/10.3389\/fphar.2018.00008.","journal-title":"Front Pharmacol"},{"issue":"6","key":"811_CR40","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1002\/ptr.3045","volume":"24","author":"X Li","year":"2010","unstructured":"Li X, Cui X, Sun X, Li X, Zhu Q, Li W. Mangiferin prevents diabetic nephropathy progression in streptozotocin-induced diabetic rats. Phytother Res. 2010;24(6):893\u201399. https:\/\/doi.org\/10.1002\/ptr.3045.","journal-title":"Phytother Res"},{"issue":"9","key":"811_CR41","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1017\/S0007114511007148","volume":"108","author":"RM Hafizur","year":"2012","unstructured":"Hafizur RM, Kabir N, Chishti S. Asparagus officinalis extract controls blood glucose by improving insulin secretion and \u03b2-cell function in streptozotocin-induced type 2 diabetic rats. Br J Nutr. 2012;108(9):1586\u201395.","journal-title":"Br J Nutr"},{"issue":"1","key":"811_CR42","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/s12906-017-1743-y","volume":"17","author":"RM Hafizur","year":"2017","unstructured":"Hafizur RM, Momin S, Fatima N. Prevention of advanced glycation end-products formation in diabetic rats through beta-cell modulation by Aegle marmelos. BMC Complement Med Therap. 2017;17(1):227. https:\/\/doi.org\/10.1186\/s12906-017-1743-y.","journal-title":"BMC Complement Med Therap"},{"issue":"2","key":"811_CR43","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s40199-021-00412-w","volume":"29","author":"SAR Shah","year":"2021","unstructured":"Shah SAR, Khan MI, Jawaid H, Qureshi U, Ul-Haq Z, Hafizur MR. Nicotinamide-cinnamic acid cocktail exerts pancreatic \u03b2-cells survival coupled with insulin secretion through ERK1\/2 signaling pathway in an animal model of apoptosis. DARU J Pharm Sci. 2021;29(2):483\u201392. https:\/\/doi.org\/10.1007\/s40199-021-00412-w.","journal-title":"DARU J Pharm Sci"},{"issue":"3","key":"811_CR44","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s00894-019-3925-7","volume":"25","author":"B Riahi-Zanjani","year":"2019","unstructured":"Riahi-Zanjani B, Balali-Mood M, Es\u2019haghi Z, Asoodeh A, Ghorani-Azam A. Molecular modeling and experimental study of a new peptide-based microextraction fiber for preconcentrating morphine in urine samples. J Mol Model. 2019;25(3):54. https:\/\/doi.org\/10.1007\/s00894-019-3925-7.","journal-title":"J Mol Model"},{"issue":"1","key":"811_CR45","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1152\/physrev.00045.2011","volume":"93","author":"JM Forbes","year":"2013","unstructured":"Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev. 2013;93(1):137\u201388. https:\/\/doi.org\/10.1152\/physrev.00045.2011.","journal-title":"Physiol Rev"},{"issue":"4","key":"811_CR46","doi-asserted-by":"publisher","first-page":"F645","DOI":"10.1152\/ajprenal.00398.2004","volume":"289","author":"JM Bohlender","year":"2005","unstructured":"Bohlender JM, Franke S, Stein G, Wolf G. Advanced glycation end products and the kidney. AJP Renal Physiol. 2005;289(4):F645\u2013F659. https:\/\/doi.org\/10.1152\/ajprenal.00398.2004.","journal-title":"AJP Renal Physiol"},{"key":"811_CR47","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.freeradbiomed.2021.05.025","volume":"171","author":"X-Q Wu","year":"2021","unstructured":"Wu X-Q, Zhang D-D, Wang Y-N, Tan Y-Q, Yu X-Y, Zhao Y-Y. AGE\/RAGE in diabetic kidney disease and ageing kidney. Free Radic Biol Med. 2021;171:260\u201371.","journal-title":"Free Radic Biol Med"},{"issue":"12","key":"811_CR48","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1369\/0022155412465073","volume":"60","author":"SO Kolset","year":"2012","unstructured":"Kolset SO, Reinholt FP, Jenssen T. Diabetic nephropathy and extracellular matrix. J Histochem Cytochem. 2012;60(12):976\u201386. https:\/\/doi.org\/10.1369\/0022155412465073.","journal-title":"J Histochem Cytochem"},{"issue":"8","key":"811_CR49","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/ncpendmet0894","volume":"4","author":"S Dronavalli","year":"2008","unstructured":"Dronavalli S, Duka I, Bakris GL. The pathogenesis of diabetic nephropathy. Nat Clin Prac Endo Metab. 2008;4(8):444\u201352.","journal-title":"Nat Clin Prac Endo Metab"},{"issue":"8","key":"811_CR50","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.metabol.2012.01.006","volume":"61","author":"Y Ishibashi","year":"2012","unstructured":"Ishibashi Y, Yamagishi S, Matsui T, Ohta K, Tanoue R, Takeuchi M, Ueda S, Nakamura K, Okuda S. Pravastatin inhibits advanced glycation end products (AGEs)-induced proximal tubular cell apoptosis and injury by reducing receptor for AGEs (RAGE) level. Metabolism. 2012;61(8):1067\u201372. https:\/\/doi.org\/10.1016\/j.metabol.2012.01.006.","journal-title":"Metabolism"},{"issue":"44","key":"811_CR51","doi-asserted-by":"publisher","first-page":"31740","DOI":"10.1074\/jbc.274.44.31740","volume":"274","author":"T Kislinger","year":"1999","unstructured":"Kislinger T, Fu C, Huber B, Qu W, Taguchi A, Du Yan S, Hofmann M, Yan SF, Pischetsrieder M, Stern D.N \u03b5-(carboxymethyl) lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem. 1999;274(44):31740\u201349.","journal-title":"J Biol Chem"},{"issue":"3","key":"811_CR52","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1172\/JCI119180","volume":"99","author":"ED Schleicher","year":"1997","unstructured":"Schleicher ED, Wagner E, Nerlich AG. Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest. 1997;99(3):457\u201368. https:\/\/doi.org\/10.1172\/JCI119180.","journal-title":"J Clin Invest"},{"key":"811_CR53","doi-asserted-by":"publisher","first-page":"1155175","DOI":"10.3389\/fnmol.2023.1155175","volume":"16","author":"R Bhattacharya","year":"2023","unstructured":"Bhattacharya R, Alam MR, Kamal MA, Seo KJ, Singh LR. AGE-RAGE axis culminates into multiple pathogenic processes: a central road to neurodegeneration. Front Mol Neurosci. 2023;16:1155175.","journal-title":"Front Mol Neurosci"},{"key":"811_CR54","doi-asserted-by":"publisher","first-page":"107282","DOI":"10.1016\/j.phrs.2024.107282","volume":"206","author":"M Zhou","year":"2024","unstructured":"Zhou M, Zhang Y, Shi L, Li L, Zhang D, Gong Z, Wu Q. Activation and modulation of the AGEs-RAGE axis: implications for inflammatory pathologies and therapeutic interventions\u2013 a review. Pharmacol Res. 2024;206:107282. https:\/\/doi.org\/10.1016\/j.phrs.2024.107282.","journal-title":"Pharmacol Res"},{"issue":"7","key":"811_CR55","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.3390\/ijms23073439","volume":"23","author":"M Steenbeke","year":"2022","unstructured":"Steenbeke M, Speeckaert R, Desmedt S, Glorieux G, Delanghe JR, Speeckaert MM. The role of advanced glycation end products and its soluble receptor in kidney diseases. Int J Mol Sci. 2022;23(7):3439.","journal-title":"Int J Mol Sci"},{"key":"811_CR56","doi-asserted-by":"publisher","first-page":"958790","DOI":"10.3389\/fimmu.2022.958790","volume":"13","author":"J Chen","year":"2022","unstructured":"Chen J, Liu Q, He J, Li Y. Immune responses in diabetic nephropathy: pathogenic mechanisms and therapeutic target. Front Immunol. 2022;13:958790. https:\/\/doi.org\/10.3389\/fimmu.2022.958790.","journal-title":"Front Immunol"},{"issue":"10","key":"811_CR57","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1007\/s00125-003-1194-5","volume":"46","author":"M Saraheimo","year":"2003","unstructured":"Saraheimo M, Teppo AM, Forsblom C, Fagerudd J, Groop PH; on behalf of the FinnDiane Study, G. Diabetic nephropathy is associated with low-grade inflammation in Type 1 diabetic patients. Diabetologia. 2003;46(10):1402\u201307. https:\/\/doi.org\/10.1007\/s00125-003-1194-5.","journal-title":"Diabetologia"},{"key":"811_CR58","doi-asserted-by":"publisher","first-page":"1034325","DOI":"10.1155\/2020\/1034325","volume":"2020","author":"M Hajinejad","year":"2020","unstructured":"Hajinejad M, Ghaddaripouri M, Dabzadeh M, Forouzanfar F, Sahab-Negah S. Natural cinnamaldehyde and its derivatives ameliorate neuroinflammatory pathways in neurodegenerative diseases. Biomed Res Int. 2020;2020:1034325. https:\/\/doi.org\/10.1155\/2020\/1034325.","journal-title":"Biomed Res Int"},{"issue":"4","key":"811_CR59","doi-asserted-by":"publisher","first-page":"e22720","DOI":"10.1002\/jbt.22720","volume":"35","author":"E Angelopoulou","year":"2021","unstructured":"Angelopoulou E, Paudel YN, Piperi C, Mishra A. Neuroprotective potential of cinnamon and its metabolites in Parkinson\u2019s disease: mechanistic insights, limitations, and novel therapeutic opportunities. J Biochem Mol Toxicol. 2021;35(4):e22720. https:\/\/doi.org\/10.1002\/jbt.22720.","journal-title":"J Biochem Mol Toxicol"},{"key":"811_CR60","doi-asserted-by":"publisher","first-page":"529359","DOI":"10.1155\/2010\/529359","volume":"2010","author":"BH Kim","year":"2010","unstructured":"Kim BH, Lee YG, Lee J, Lee JY, Cho JY. Regulatory effect of cinnamaldehyde on monocyte\/macrophage-mediated inflammatory responses. Mediators Inflamm. 2010;2010:529359. https:\/\/doi.org\/10.1155\/2010\/529359.","journal-title":"Mediators Inflamm"},{"issue":"4","key":"811_CR61","doi-asserted-by":"publisher","first-page":"552","DOI":"10.2337\/diab.41.4.552","volume":"41","author":"JA Corbett","year":"1992","unstructured":"Corbett JA, Tilton RG, Chang K, Hasan KS, Ido Y, Wang JL, Sweetland MA, Lancaster Jr JR, Williamson JR, McDaniel ML. Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes. 1992;41(4):552\u201356. https:\/\/doi.org\/10.2337\/diab.41.4.552.","journal-title":"Diabetes"},{"key":"811_CR62","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1196\/annals.1338.067","volume":"1043","author":"R Wada","year":"2005","unstructured":"Wada R, Yagihashi S. Role of advanced glycation end products and their receptors in development of diabetic neuropathy. Ann N Y Acad Sci. 2005;1043:598\u2013604. https:\/\/doi.org\/10.1196\/annals.1338.067.","journal-title":"Ann N Y Acad Sci"},{"key":"811_CR63","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jpba.2019.01.025","volume":"166","author":"P Tao","year":"2019","unstructured":"Tao P, Li Z, Woolfork AG, Hage DS. Characterization of tolazamide binding with glycated and normal human serum albumin by using high-performance affinity chromatography. J Pharm Biomed Anal. 2019;166:273\u201380. https:\/\/doi.org\/10.1016\/j.jpba.2019.01.025.","journal-title":"J Pharm Biomed Anal"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-024-00811-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-024-00811-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-024-00811-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T13:05:37Z","timestamp":1731589537000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-024-00811-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,14]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["811"],"URL":"https:\/\/doi.org\/10.1186\/s40360-024-00811-0","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,14]]},"assertion":[{"value":"24 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ethical committee, of University of Karachi, revised and approved this work under (ASP number 2016-0031). Notably, all animal experimentation was conducted in accordance with applicable laws, regulations, and guidelines, prioritizing animal welfare and minimizing any potential harm.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"85"}}